Evidence-Based Strategies to Improve Long-Term Outcomes in Obstructive Sleep Apnoea

Evidence-Based Strategies to Improve Long-Term Outcomes in Obstructive Sleep Apnoea

Continuous positive airway pressure (CPAP) therapy remains the first-line treatment for moderate to severe obstructive sleep apnoea (OSA). When used consistently, CPAP effectively reduces apnoea–hypopnoea index (AHI), improves daytime somnolence, and mitigates cardiometabolic risk.

However, long-term therapeutic success is highly dependent on adherence.

Despite advances in mask design, humidification, and auto-adjusting technologies, adherence remains variable. Understanding the determinants of CPAP use and implementing structured follow-up is critical to improving patient outcomes.

Why Adherence Is Clinically Significant

OSA is associated with:

  • Systemic hypertension
  • Coronary artery disease
  • Stroke
  • Atrial fibrillation
  • Insulin resistance
  • Impaired neurocognitive performance

The Sleep Apnea Cardiovascular Endpoints (SAVE) trial demonstrated that cardiovascular benefit is most evident in patients who are adherent to CPAP therapy (McEvoy et al., 2016). Suboptimal use reduces potential risk modification.

From a primary care perspective, CPAP should be viewed as a long-term cardiometabolic intervention rather than solely a symptomatic treatment.

Determinants of CPAP Adherence

1. Early Usage Patterns

Adherence patterns are typically established within the first one to two weeks of therapy. Patients who experience early mask discomfort, pressure intolerance, or claustrophobia are at significantly higher risk of discontinuation.

Weaver and Grunstein (2008) highlight that proactive early intervention — including troubleshooting and behavioural support — strongly predicts long-term compliance.

Clinical implication: Early structured follow-up improves sustained use.

2. Mask Interface and Comfort

Mask discomfort remains one of the most common reasons for treatment cessation. Individualised mask selection based on facial anatomy, nasal patency, and breathing patterns improves tolerance.

Access to:

  • Mask refitting
  • Leak optimisation
  • Humidification adjustment
  • Pressure re-evaluation

can significantly reduce early drop-off rates.

3. Patient Education and Expectation Setting

Clear education regarding:

  • OSA pathophysiology
  • Long-term cardiovascular risk
  • The importance of nightly consistency
  • Realistic timelines for symptomatic improvement

enhances patient engagement.

The American Academy of Sleep Medicine (AASM) emphasises behavioural and educational interventions as part of comprehensive OSA management (Patil et al., 2019).

The Role of Ongoing Monitoring

Modern CPAP devices provide objective adherence and efficacy data. Regular review of:

  • Usage hours
  • Residual AHI
  • Leak parameters

allows early identification of treatment barriers.

Collaborative care between sleep physicians, GPs, and CPAP providers ensures therapy remains optimised rather than static. CPAP therapy is highly effective when used consistently. Optimising adherence requires early follow-up, individualised equipment fitting, structured education, and ongoing monitoring.

Improving adherence is not merely a comfort issue. It is central to reducing long-term cardiovascular and metabolic morbidity associated with untreated OSA.

References
McEvoy, R. D., Antic, N. A., Heeley, E., et al. (2016). CPAP for prevention of cardiovascular events in obstructive sleep apnea. New England Journal of Medicine, 375(10), 919–931. https://doi.org/10.1056/NEJMoa1606599
Patil, S. P., Ayappa, I. A., Caples, S. M., et al. (2019). Treatment of adult obstructive sleep apnea with positive airway pressure: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 15(2), 335–343. https://doi.org/10.5664/jcsm.7640
Weaver, T. E., & Grunstein, R. R. (2008). Adherence to continuous positive airway pressure therapy. Proceedings of the American Thoracic Society, 5(2), 173–178. https://doi.org/10.1513/pats.200708-119MG
Back to blog